$PBYI
PUMA BIOTECHNOLOGY, INC.

2014 Q3 Form 10-Q Financial Statement

#000156459014005392 Filed on November 10, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2013 Q3 2012
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.870M $2.260M $23.60M
YoY Change 71.24% -72.06% 162.22%
% of Gross Profit
Research & Development $32.09M $12.07M $49.64M
YoY Change 165.91% -32.12% 5909.2%
% of Gross Profit
Depreciation & Amortization $160.0K $110.0K $270.0K
YoY Change 45.45% 57.14% 2600.0%
% of Gross Profit
Operating Expenses $35.96M $14.33M $74.45M
YoY Change 150.92% -44.61% 632.99%
Operating Profit -$14.33M -$74.45M
YoY Change -44.61% 632.99%
Interest Expense $110.0K $10.00K $100.0K
YoY Change 1000.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $48.00K $98.00K
YoY Change -100.0% 242.86% -228.95%
Pretax Income -$35.84M -$14.28M -$74.40M
YoY Change 150.98% -44.78% 629.41%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$35.84M -$14.28M -$74.35M
YoY Change 150.96% -44.77% 626.59%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.190M -$497.9K -$3.429M
COMMON SHARES
Basic Shares Outstanding 28.68M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2013 Q3 2012
SHORT-TERM ASSETS
Cash & Short-Term Investments $153.9M $95.60M $137.4M
YoY Change 60.98% 187.09% 157.3%
Cash & Equivalents $28.26M $51.26M $137.4M
Short-Term Investments $125.6M $44.40M
Other Short-Term Assets $4.500M $3.600M $1.000M
YoY Change 25.0% 350.0% 233.33%
Inventory
Prepaid Expenses
Receivables $1.800M $11.30M $10.60M
Other Receivables $0.00 $11.29M $0.00
Total Short-Term Assets $160.1M $110.6M $149.0M
YoY Change 44.79% 224.11% 177.47%
LONG-TERM ASSETS
Property, Plant & Equipment $1.900M $1.619M $1.500M
YoY Change 17.36% 38.5% 114.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00M $2.900M $1.200M
YoY Change 244.83% 141.67% 9.09%
Total Long-Term Assets $12.00M $4.533M $2.700M
YoY Change 164.73% 90.4% 58.82%
TOTAL ASSETS
Total Short-Term Assets $160.1M $110.6M $149.0M
Total Long-Term Assets $12.00M $4.533M $2.700M
Total Assets $172.1M $115.1M $151.7M
YoY Change 49.51% 215.39% 173.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.40M $9.730M $500.0K
YoY Change 89.11% 855.75% 400.0%
Accrued Expenses $10.90M $9.496M $21.20M
YoY Change 14.79% -62.97% 4140.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $29.40M $19.23M $21.70M
YoY Change 52.92% -27.88% 3516.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.100M $1.100M $1.100M
YoY Change 0.0% 37.5% 175.0%
Total Long-Term Liabilities $1.100M $1.100M $1.100M
YoY Change 0.0% 37.5% 175.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.40M $19.23M $21.70M
Total Long-Term Liabilities $1.100M $1.100M $1.100M
Total Liabilities $30.50M $20.35M $22.80M
YoY Change 49.88% -25.99% 2180.0%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $375.5M $218.1M
YoY Change 72.17% 204.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $141.6M $94.76M $128.9M
YoY Change
Total Liabilities & Shareholders Equity $172.1M $115.1M $151.7M
YoY Change 49.51% 215.39% 173.83%

Cashflow Statement

Concept 2014 Q3 2013 Q3 2012
OPERATING ACTIVITIES
Net Income -$35.84M -$14.28M -$74.35M
YoY Change 150.96% -44.77% 626.59%
Depreciation, Depletion And Amortization $160.0K $110.0K $270.0K
YoY Change 45.45% 57.14% 2600.0%
Cash From Operating Activities -$24.32M -$12.00M -$44.01M
YoY Change 102.67% 57.07% 2312.94%
INVESTING ACTIVITIES
Capital Expenditures -$120.0K -$80.00K -$1.060M
YoY Change 50.0% 700.0% 53.62%
Acquisitions
YoY Change
Other Investing Activities -$2.650M $2.300M -$160.0K
YoY Change -215.22% -84.76%
Cash From Investing Activities -$2.770M $2.230M -$1.221M
YoY Change -224.22% -22400.0% -30.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $129.2M
YoY Change 127.73%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 150.0K 129.3M
YoY Change -100.0% 126.96%
NET CHANGE
Cash From Operating Activities -24.32M -12.00M -44.01M
Cash From Investing Activities -2.770M 2.230M -1.221M
Cash From Financing Activities 0.000 150.0K 129.3M
Net Change In Cash -27.09M -12.00M 84.03M
YoY Change 125.75% 56.86% 57.41%
FREE CASH FLOW
Cash From Operating Activities -$24.32M -$12.00M -$44.01M
Capital Expenditures -$120.0K -$80.00K -$1.060M
Free Cash Flow -$24.20M -$11.92M -$42.95M
YoY Change 103.02% 56.23% 3687.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6804000
CY2014Q3 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
233733000
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
139251000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
397000
us-gaap Net Income Loss
NetIncomeLoss
-233733000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38713000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-233733000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.35
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29936254
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38721000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-233851000
CY2010Q3 us-gaap Stockholders Equity
StockholdersEquity
0
us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
0
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
7000
CY2011 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
61000
CY2011 pbyi Issuance Of Common Stock In Exchange For Convertible Notes Value
IssuanceOfCommonStockInExchangeForConvertibleNotesValue
150000
CY2011 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7586000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-54659000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-10233000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-74352000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
67000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
223232000
us-gaap Operating Income Loss
OperatingIncomeLoss
-234130000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-100000
us-gaap Operating Expenses
OperatingExpenses
234130000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38844000
us-gaap Investment Income Interest
InvestmentIncomeInterest
128000
us-gaap Investment Income Interest
InvestmentIncomeInterest
497000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
131000
us-gaap Net Income Loss
NetIncomeLoss
-38713000
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
us-gaap Net Income Loss
NetIncomeLoss
-7000
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28991289
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
375451000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
83987000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104374000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28991289
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28678439
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-118000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
129440000
CY2012 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
16.00
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
129214000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1408000
CY2012 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
18222000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
45000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
128909000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7519000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2215000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22779000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
54372000
us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
122.50
us-gaap Depreciation And Amortization
DepreciationAndAmortization
298000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1137000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-903000
us-gaap Share Based Compensation
ShareBasedCompensation
4426000
us-gaap Share Based Compensation
ShareBasedCompensation
31773000
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
25808000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
682000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1760000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
4357000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
13308000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9248000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
18448000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-11723000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10911000
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
-34000
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
-188000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-41469000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-159633000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
435000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
2023000
us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
3000
us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
1024000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1215000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
132260000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
44385000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
181607000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
47446000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
55892000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-85479000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-44824000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
37500
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3778307
CY2013Q4 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
2369000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
84000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1066000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14781000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-86147000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
28263000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-129977000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
150000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129440000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
315395000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
146000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2260000
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
68000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
129440000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
146000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
317873000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137408000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51261000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
150000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates: </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and reported amounts of expenses for the period presented. Accordingly, actual results could differ from those estimates. Significant estimates include the cost of services provided by consultants who manage clinical trials and conduct research and clinical trials on behalf of the Company that are billed on a delayed basis. As the actual costs become known, the Company adjusts its estimated cost in that period. The value of stock-based compensation includes estimates based on future events, which are difficult to predict. It is at least reasonably possible that a change in the estimates will occur in the near term. </p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk: </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents. The Company&#8217;s cash and cash equivalents in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at September&#160;30, 2014, were approximately $29.3 million. The Company does not believe it is exposed to any significant credit risk. </p></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">Certain amounts for 2013 have been reclassified to conform to the current year&#8217;s presentation.</p></div>
CY2014Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-24300000
CY2011Q3 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
18666733
CY2011Q3 pbyi Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Shares Received
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentSharesReceived
18666733
CY2011Q3 pbyi Merger Stock Conversion Ratio
MergerStockConversionRatio
1.00
CY2011Q3 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
40000
CY2011Q3 us-gaap Payments For Merger Related Costs
PaymentsForMergerRelatedCosts
40000
CY2011 us-gaap Other Expenses
OtherExpenses
80000
CY2014Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
29300000
pbyi License Agreement Number Of Days To Review Invoice And Supporting Documentation
LicenseAgreementNumberOfDaysToReviewInvoiceAndSupportingDocumentation
P60D
CY2013Q3 us-gaap Cost Of Reimbursable Expense
CostOfReimbursableExpense
3400000
us-gaap Cost Of Reimbursable Expense
CostOfReimbursableExpense
13100000
CY2014Q3 pbyi Reduction In Excess Cap Costs
ReductionInExcessCapCosts
0
pbyi Reduction In Excess Cap Costs
ReductionInExcessCapCosts
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2014Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
13308000
CY2013Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
7715000
CY2014Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1024000
CY2013Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
914000
CY2014Q3 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
748000
CY2013Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
513000
CY2014Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3047000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2383000
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1137000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
699000
CY2014Q3 pbyi Accrued Development Costs
AccruedDevelopmentCosts
3838000
CY2013Q4 pbyi Accrued Development Costs
AccruedDevelopmentCosts
4801000
CY2014Q3 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
3712000
CY2014Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
250000
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2975000
CY2014Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
136000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
259000
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
10449000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1806000
pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
0.15
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2604224
pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
0.76
CY2014Q3 pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
0.35
CY2013Q3 pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
0.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1211583
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2298608
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1479699
pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3
P8Y7M6D
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
699381000
CY2014Q3 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue
364868000
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
334513000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
86.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
25.95

Files In Submission

Name View Source Status
0001564590-14-005392-index-headers.html Edgar Link pending
0001564590-14-005392-index.html Edgar Link pending
0001564590-14-005392.txt Edgar Link pending
0001564590-14-005392-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
pbyi-10q_20140930.htm Edgar Link pending
pbyi-20140930.xml Edgar Link completed
pbyi-20140930.xsd Edgar Link pending
pbyi-20140930_cal.xml Edgar Link unprocessable
pbyi-20140930_def.xml Edgar Link unprocessable
pbyi-20140930_lab.xml Edgar Link unprocessable
pbyi-20140930_pre.xml Edgar Link unprocessable
pbyi-ex101_20140930765.htm Edgar Link pending
pbyi-ex311_2014093093.htm Edgar Link pending
pbyi-ex312_2014093094.htm Edgar Link pending
pbyi-ex321_2014093095.htm Edgar Link pending
pbyi-ex322_2014093096.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending